Table 1

Baseline characteristics (randomized population)

Baseline characteristicsGla-300 (N = 466)IDeg-100 (N = 463)Total (N = 929)
Age, years60.6 ± 9.660.5 ± 9.860.5 ± 9.7
Sex (% male/female)53/4754/4654/46
BMI, kg/m231.7 ± 4.331.3 ± 4.431.5 ± 4.4
Known type 2 diabetes duration, years10.5 ± 6.110.7 ± 6.510.6 ± 6.3
HbA1c
 %8.71 ± 0.838.57 ± 0.808.64 ± 0.82
 mmol/mol71.7 ± 9.170.2 ± 8.770.9 ± 9.0
HbA1c randomization strata
 <8.0% (<64 mmol/mol)86 (18.5)85 (18.4)171 (18.4)
 ≥8.0% (≥ 64 mmol/mol)380 (81.5)378 (81.6)758 (81.6)
FPG, mg/dL191 ± 49182 ± 51186 ± 51
Fasting SMPG, mg/dL178 ± 40172 ± 38175 ± 39
eGFR, mL/min/1.73 m292.4 ± 26.890.8 ± 26.091.6 ± 26.4
Number of prior noninsulin antihyperglycemic agents used
 00 (0.0)1 (0.2)1 (0.1)
 170 (15.0)65 (14.0)135 (14.5)
 2179 (38.4)187 (40.4)366 (39.4)
 >2217 (46.6)210 (45.4)427 (46.0)
Prior noninsulin antihyperglycemic treatment (%)
 Metformin91.891.191.5
 SUs64.666.765.7
 Glinides2.61.92.3
 Thiazolidinediones4.55.24.8
 DPP-4 inhibitors26.022.924.4
 SGLT2 inhibitors13.313.413.3
 GLP-1 RAs9.914.011.9
 α-Glucosidase inhibitors1.91.51.7
 Other0.20.20.2
  • Data are presented as mean ± SD or n (%) unless otherwise stated. DPP-4, dipeptidyl peptidase 4; eGFR, estimated glomerular filtration rate.